Variability of α/β ratios for prostate cancer with the fractionation schedule: caution against using the linear-quadratic model for hypofractionated radiotherapy

Table 2 Conventionally fractionated radiotherapy group

Study number	Author	Number of patients	5y-bRFS	Total dose (D)	Fractions (N)/single dose	D²/N (C)	Definition of bRFS^b
1	Aizer	352	0.748	75.6	42	136.08	P
2	Arcangeli	85	0.79	80	40	160	P
3	Catton	598	0.85	78	39	156	P
4	Dearnaley	1065	0.883	74	37	148	P
5	Eade	43	0.7	69	2.1	144.9	P
	Eade	552	0.81	72.5	2.1	152.25	P
	Eade	568	0.83	77.5	2.1	162.75	P
	Eade	367	0.89	81	2.1	170.1	P
6	Incrocci	397	0.771	78	39	156	P
7	Kim	56	0.641	70.2	39	126.36	P
8	Kuban	150	0.78	70	35	140	P
8	Kuban	151	0.85	78	39	156	P
9	Kupelian	310	0.78	78	39	156	A
10	Leborgne	160	0.887	78	39	156	P
11	Lukka	470	0.4705	66	33	132	A
12	Pollack	152	0.852	76	38	152	P
13	Valdagni	161	0.7	74	37	148	A
14	Yeoh	109	0.555	64	32	128	A
15	Zelefsky	358	0.61	70.2	39	126.36	P
	Zelefsky	471	0.74	75.6	42	136.08	P
	Zelefsky	741	0.85	81	45	145.8	P
	Zelefsky	477	0.82	86.4	48	155.52	P

ISSN: 1748-717X